Looking back on consumer discretionary - leisure facilities stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Vail Resorts (NYSE:MTN) and its peers.

Seaport Research downgraded Qualcomm and set a $100 price target.

The advertising technology platform was publicly accused by one of its largest clients.

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the investment banking & brokerage industry, including Houlihan Lokey (NYSE:HLI) and its peers.

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the specialty equipment distributors stocks, including Richardson Electronics (NASDAQ:RELL) and its peers.

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the waste management stocks, including Montrose (NYSE:MEG) and its peers.

Expect AI companies to invest heavily in nuclear energy.

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers.

The healthcare stock has lost more than half of its value in the past year.

Looking back on investment banking & brokerage stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including BGC (NASDAQ:BGC) and its peers.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst performers in the therapeutics industry.

This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.

The Russell 2000 (^RUT) may be overshadowed by larger indexes, but it’s full of companies with the potential to deliver high returns. A select few have the right mix of innovation, market opportunity, and execution to outperform over time.

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorati

Cathie Wood recently added to her position in CRISPR Therapeutics stock.